Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.5935/1678-9741.20140056 http://scihub22266oqcxt.onion/10.5935/1678-9741.20140056 C4408814!4408814!25714205     free     free     free       Rev+Bras+Cir+Cardiovasc 2014 ; 29 (4): 527-36 Nephropedia Template TP {{tp|p=25714205|t=2014. Hybrid treatment of aortic arch disease |pdf=|usr=}}{{25714205}} gab.com Text Hybrid treatment of aortic arch disease JO: Rev Bras Cir Cardiovasc http://www.kidney.de/pget.php?&tw=1&pmid=25714205 #FOAvip Introduction: The management of thoracic aortic disease involving the ascending aorta, aortic arch and descending thoracic aorta are technically challenging and is an area in constant development and innovation. Objective: To analyze early and midterm results of hybrid treatment of arch aortic disease. Methods: Retrospective study of procedures performed from January 2010 to December 2012. The end points were the technical success, therapeutic success, morbidity and mortality, neurologic outcomes, the rate of endoleaks and reinterventions. Results: A total of 95 patients treated for thoracic aortic diseases in this period, 18 underwent hybrid treatment and entered in this study. The average ages were 62.3 years. The male was present in 66.7%. The technical and therapeutic success was 94.5% e 83.3%. The perioperative mortality rate of 11.1%. There is any death during one-year follow- up. The reoperation rates were 16.6% due 2 cases of endoleak Ia and one case of endoleak II. There is any occlusion of anatomic or extra anatomic bypass during follow up. Conclusion: In our study, the hybrid treatment of aortic arch disease proved to be a feasible alternative of conventional surgery. The therapeutic success rates and re- interventions obtained demonstrate the necessity of thorough clinical follow-up of these patients in a long time. Twit Text FOAVip Hybrid treatment of aortic arch disease ????Rev Bras Cir Cardiovasc http://www.kidney.de/pget.php?&tw=1&pmid=25714205 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25714205 #FOAvip English Wikipedia <ref>{{Cite pmid|25714205}}</ref> Hybrid treatment of aortic arch disease #MMPMID25714205 Metzger PB; Rossi FH; Moreira SM; Issa M; Izukawa NM; Dinkhuysen JJ; Spina Neto D; Kambara AM Rev Bras Cir Cardiovasc 2014[Oct]; 29 (4): 527-36 PMID25714205show ga Introduction: The management of thoracic aortic disease involving the ascending aorta, aortic arch and descending thoracic aorta are technically challenging and is an area in constant development and innovation. Objective: To analyze early and midterm results of hybrid treatment of arch aortic disease. Methods: Retrospective study of procedures performed from January 2010 to December 2012. The end points were the technical success, therapeutic success, morbidity and mortality, neurologic outcomes, the rate of endoleaks and reinterventions. Results: A total of 95 patients treated for thoracic aortic diseases in this period, 18 underwent hybrid treatment and entered in this study. The average ages were 62.3 years. The male was present in 66.7%. The technical and therapeutic success was 94.5% e 83.3%. The perioperative mortality rate of 11.1%. There is any death during one-year follow- up. The reoperation rates were 16.6% due 2 cases of endoleak Ia and one case of endoleak II. There is any occlusion of anatomic or extra anatomic bypass during follow up. Conclusion: In our study, the hybrid treatment of aortic arch disease proved to be a feasible alternative of conventional surgery. The therapeutic success rates and re- interventions obtained demonstrate the necessity of thorough clinical follow-up of these patients in a long time. äHybrid treatment of aortic arch disease (epmc).pdf DeepDyve Pubget Overpricing